Palvella Therapeutics, Inc. Common Stock (PVLA)

Price$112.59

Value ScoreF

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)13.48%

Price vs S&P 500 (4W)-11.58%

VGM Score35.54

Market Capitalization$1.70B

All Metrics

Book Value / Share (Quarterly)$16.23

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.44%

Cash Flow / Share (Quarterly)$-2.03

Price vs S&P 500 (YTD)2.24%

Net Profit Margin (TTM)-39.71%

EPS (TTM)$-4.16

10-Day Avg Trading Volume0.18M

EPS Excl Extra (TTM)$-4.16

Revenue Growth (5Y)8.03%

EPS (Annual)$-7.62

ROI (Annual)-22.80%

Net Profit Margin (5Y Avg)-102.68%

Cash / Share (Quarterly)$18.29

ROA (Last FY)-19.27%

Revenue Growth TTM (YoY)-97.15%

EBITD / Share (TTM)$-3.87

ROE (5Y Avg)-89.63%

Operating Margin (TTM)-47.76%

Cash Flow / Share (Annual)$-2.02

P/B Ratio7.31x

P/B Ratio (Quarterly)7.68x

Net Income / Employee (Annual)$-586,200

Net Interest Coverage (TTM)-73.89x

ROA (TTM)-42.50%

EPS Incl Extra (Annual)$-7.62

Current Ratio (Annual)5.20x

Quick Ratio (Quarterly)28.73x

3-Month Avg Trading Volume0.29M

52-Week Price Return378.05%

Revenue / Employee (TTM)$46,600

P/S Ratio (Annual)39.69x

Asset Turnover (Annual)1.11x

52-Week High$151.18

Operating Margin (5Y Avg)-106.68%

EPS Excl Extra (Annual)$-7.62

26-Week Price Return29.41%

Quick Ratio (Annual)5.11x

13-Week Price Return-20.14%

Total Debt / Equity (Annual)0.63x

Current Ratio (Quarterly)28.88x

Enterprise Value$1.51B

Revenue / Share Growth (5Y)-2.80%

Asset Turnover (TTM)0.76x

Revenue / Employee (Annual)$1,476,200

Pretax Margin (Annual)-57.33%

Cash / Share (Annual)$4.68

3-Month Return Std Dev72.17%

Net Income / Employee (TTM)$-1,699,900

ROE (Last FY)-27.15%

Net Interest Coverage (Annual)-10.79x

EPS Basic Excl Extra (Annual)$-7.62

P/FCF (TTM)11327.02x

Receivables Turnover (TTM)1.91x

Total Debt / Equity (Quarterly)0.09x

EPS Incl Extra (TTM)$-4.16

Receivables Turnover (Annual)13.42x

ROI (TTM)-47.53%

P/S Ratio (TTM)41.51x

Pretax Margin (5Y Avg)-102.56%

Revenue / Share (Annual)$38.02

Price vs S&P 500 (52W)349.84%

Year-to-Date Return13.17%

5-Day Price Return3.92%

EPS Normalized (Annual)$-7.62

ROA (5Y Avg)-36.56%

Net Profit Margin (Annual)-57.33%

Month-to-Date Return-7.68%

EBITD / Share (Annual)$-6.28

Operating Margin (Annual)-69.51%

LT Debt / Equity (Annual)0.63x

ROI (5Y Avg)-88.76%

LT Debt / Equity (Quarterly)0.09x

EPS Basic Excl Extra (TTM)$-4.16

P/B Ratio (Annual)44.27x

Pretax Margin (TTM)-39.71%

Book Value / Share (Annual)$2.26

Price vs S&P 500 (13W)-29.89%

Beta-0.09x

P/FCF (Annual)35.54x

Revenue / Share (TTM)$0.76

ROE (TTM)-56.87%

52-Week Low$20.20

vGradeF

gGradeD

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-1.20est. -0.95

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.23

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PVLAPalvella Therapeutics, Inc. Common Stock	F	D	B	$112.59
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Palvella Therapeutics is a late-stage biopharmaceutical company developing treatments for rare genetic skin diseases that currently lack approved therapies. The company's lead candidate, QTORIN rapamycin gel, is based on its proprietary QTORIN platform and is in clinical development for two rare genetic skin disorders.